Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
Status:
Terminated
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg
QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.